Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CASIF | 6-K | bullish | 6/10 | CASI Pharmaceuticals settled an arbitration with Acrotech Biopharma over the Evomela license for China. The settlement r | Jul 3, 2026 |
| NBP | 6-K | neutral | 4/10 | NovaBridge Biosciences announced the appointment of Srishti Gupta, MD MPP as CEO effective July 1, 2026, replacing Xi-Yo | Jul 3, 2026 |
| MSLE | 6-K | bullish | 7/10 | Satellos Bioscience received FDA Fast Track designation for SAT-3247 in Duchenne muscular dystrophy, adding to existing | Jul 3, 2026 |
| RDHL | 6-K | bearish | 6/10 | RedHill Biopharma filed a prospectus supplement to increase its ATM offering by up to $2,128,000, adding further dilutio | Jul 3, 2026 |
| TNXP | 8-K | neutral | 4/10 | Tonix Pharmaceuticals announced first patient enrollment in the HORIZON Phase 2 study of TNX-102 SL (5.6 mg) as a first- | Jul 3, 2026 |
| BCRX | 8-K | neutral | 5/10 | BioCryst is discontinuing its internal discovery programs and closing its Birmingham, Alabama research facility by year- | Jul 3, 2026 |
| RGNX | 8-K | bullish | 7/10 | REGENXBIO announced the first patient dosing in the Phase IIb/III NAAVIGATE trial of surabgene lomparvovec (sura-vec) in | Jul 3, 2026 |
| IMRN | 6-K | neutral | 2/10 | Immuron Ltd filed a Form 6-K with the SEC to report the cancellation of 3,805,528 ordinary shares via a buy-back of unma | Jul 3, 2026 |
| NGNE | 8-K | bullish | 7/10 | Neurogene reported highly positive long-term Phase 1/2 data for NGN-401 gene therapy in Rett syndrome: 100% of 10 partic | Jul 3, 2026 |
| CMND | 6-K | neutral | 3/10 | Clearmind Medicine announced the grant of a new U.S. patent (No. 12,357,590) titled 'BINGE BEHAVIOR REGULATORS' covering | Jul 3, 2026 |
| ALMS | 8-K | neutral | 4/10 | Alumis Inc. furnished an updated corporate investor presentation via an 8-K (Item 8.01), highlighting positive Phase 3 p | Jul 3, 2026 |
| TCRT | 8-K | neutral | 3/10 | Alaunos Therapeutics announced new preclinical statistical analysis for ALN1003, showing lower liver weight after adjust | Jul 3, 2026 |
| GLUE | 144 | neutral | 2/10 | Director Anthony M. Manning filed a Form 144 signaling intent to sell 10,000 shares (~$231K at filing) of Monte Rosa The | Jul 3, 2026 |
| ASND | 6-K | neutral | 2/10 | Ascendis Pharma reported the closing of a warrant exercise window on June 29, 2026, resulting in the issuance of 177,267 | Jul 3, 2026 |
| IMUX | 8-K | neutral | 3/10 | Immunic, Inc. held its annual meeting on June 29, 2026, where shareholders elected three Class III directors, approved a | Jul 3, 2026 |
| ANAB | DEFA14A | neutral | 2/10 | AnaptysBio filed definitive additional proxy soliciting materials (DEFA14A) for its August 11, 2026 Annual Meeting. The | Jul 3, 2026 |
| NVCT | 8-K | neutral | 2/10 | Nuvectis Pharma filed an 8-K announcing it is reducing the available amount under its Sales Agreement with Leerink Partn | Jul 3, 2026 |
| ANAB | 144 | bearish | 6/10 | Officer Dennis Mulroy filed a Form 144 to sell 9,476 shares (~$601K) of AnaptysBio, continuing a heavy selling pattern o | Jul 3, 2026 |
| SNYR | 8-K | bearish | 6/10 | Synergy CHC Corp. reported shareholder approval of a massive equity plan amendment authorizing 150,000,000 shares (10x c | Jul 3, 2026 |
| NVO | 6-K | neutral | 3/10 | Novo Nordisk filed a 6-K disclosing ongoing B-share repurchases under a DKK 15 billion program. Since February 4, 2026, | Jul 3, 2026 |
| GANX | 8-K | bullish | 7/10 | Gain Therapeutics announced FDA authorization of its Investigational New Drug (IND) application for GT-02287, allowing t | Jul 3, 2026 |
| DBVT | 8-K | neutral | 5/10 | DBV Technologies announced that it is delaying the BLA submission for its VIASKIN Peanut Patch in children aged 4-7 year | Jul 3, 2026 |
| CDT | 8-K | bearish | 7/10 | CDT Equity Inc. dismissed its auditor CBIZ CPAs and engaged Carr, Riggs & Ingram (CRI) as its new independent registered | Jul 3, 2026 |
| RAPP | 144 | bearish | 5/10 | Officer Abraham N. Ceesay filed a Form 144 indicating intent to sell 99,480 shares of Rapport Therapeutics (RAPP), value | Jul 3, 2026 |
| ZSQR | 8-K | neutral | 5/10 | Z Squared Inc. raised approximately $15.3M via the final advance under its legacy Standby Equity Purchase Agreement (SEP | Jul 3, 2026 |
| CVKD | 8-K | neutral | 2/10 | Cadrenal Therapeutics appointed John P. Sharp as Interim CFO via a consulting agreement with Lohman & Associates at $455 | Jul 3, 2026 |
| HOWL | 144 | bearish | 6/10 | Three major institutional shareholders (UBS Oncology Impact Fund L.P., MPM BioVentures 2014 (B), L.P., and MPM BioVentur | Jul 3, 2026 |
| HOWL | 144 | neutral | 2/10 | MPM Asset Management LLC, a major institutional shareholder, filed a Form 144 indicating intent to sell 16,830 shares of | Jul 3, 2026 |
| HOWL | 144 | bearish | 6/10 | MPM Asset Management Investors BV2014 LLC, a major shareholder, filed a Form 144 to sell 3,657 shares of Werewolf Therap | Jul 3, 2026 |
| KYMR | 144 | neutral | 4/10 | Atlas Venture, a founding VC investor in Kymera Therapeutics, has filed two Form 144 notices to sell a combined 76,650 s | Jul 3, 2026 |